Status:
COMPLETED
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Nathan's Battle Foundation
Conditions:
Batten Disease
Late Infantile Neuronal Ceroid Lipofuscinosis
Eligibility:
All Genders
3-18 years
Phase:
PHASE1
Brief Summary
The aim of this study is to treat the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal inherited disease in the brain. This will be accomplished by using delivery o...
Detailed Description
Late infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal childhood neurodegenerative lysosomal storage disease with no known therapy. There are estimated to be 200 to 300 children in the USA a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A definitive diagnosis of late infantile neuronal ceroid lipofuscinosis, based on clinical phenotype and genotype, with CLN2 gene mutations known to be associated with the disease.
- All subjects will be naive, i.e., they have not previously participated in a gene therapy study for LINCL.
- Parents of study participants must agree to comply in good faith with the conditions of the study, including attending all of the required baseline and follow-up assessments.
- Both parents or legal guardians must give consent for their child's participation in the research study.
- For group A, subjects will have a LINCL average total disability score 0 to 4, the severe form of the disease.
- For group B, subjects will have a LINCL average total disability score 5 to 6, a moderate form of the disease.
- Exclusion criteria
- Other significant medical or neurological conditions may disqualify the patient from participation in this study, particularly those which would create an unacceptable operative risk or risk to receiving the AAV2CUhCLN2 vector. Examples include malignancy (other than skin cancer), congenital heart disease, liver or renal failure, or seropositive for HIV. Each case will be individually reviewed and the final decision shall rest with the Eligibility Committee comprised on three physicians other than the Principal Investigator, including a pediatric neurosurgeon, pediatric neurologist and general pediatrician.
- Individuals without adequate control of seizures (i.e., a seizure score \<3 on the CNS Disability Scoring System for Late Infantile Neuronal Ceroid Lipofuscinosis).
- Individuals with heart disease that would be a risk for anesthesia.
- History of hemorrhage or major risk factors for hemorrhage (e.g., abnormally low platelet counts).
- Concurrent participation in any other FDA approved Investigational New Drug clinical protocol is not allowed, although the Principal Investigator will work with other doctors to accommodate specific requests (e.g., a study of nutritional supplements probably would not be a disqualification).
- Individuals who have a (1) heart pacemaker and/or related implants, (2) metal fragment/chip in the eye or other sites, (3) an aneurysm clip in their brain, and (4) metallic inner ear implants.
Exclusion
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00151216
Start Date
June 1 2004
End Date
June 1 2019
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York Presbyterian Hospital - Weill Medical College of Cornell University
New York, New York, United States, 10021